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Acute respiratory distress syndrome (ARDS) is a clinical 
syndrome characterized by a non-cardiogenic pulmonary 
edema with bilateral chest X-ray opacities and hypoxemia 
refractory to oxygen therapy and low level of positive end-
expiratory pressure (1). 
Recently, a large observational study reported an ARDS 
prevalence of 10.4% of all ICU admissions and of 23.4% 
of all subjects receiving mechanical ventilation (2). Despite 
these alarming numbers, according to the most recent 
literature, ARDS is still under-recognized, undertreated, 
and associated with a mortality rate that in the most severe 
forms is close to 50% (2).
Among the few therapeutic  approaches,  Prone 
Positioning (PP) can be considered one of the oldest 
attempts, firstly pointed out in the last Seventies as a strategy 
to improve ventilation in respiratory failure settings (3). 
Since then, the understanding of the physiology and the 
effectiveness of PP has been dramatically deepening and at 
the present time, PP has been recognized as one of three 
interventions (not considering ECMO) that can actually 
improve patient survival in ARDS cases, along with lower 
tidal volume (6 mL/kg of predicted body weight Vt) and 
continuous intravenous infusion of neuromuscular blocking 
agent (cisatracurium for 48 hours).
The mechanisms underlying the efficacy of PP to 
improve outcome include the redistribution of lung 
densities with a recruitment of dorsal regions, increase 
of end-expiratory lung volume, an increase in chest-wall 
elastance, a reduction of alveolar shunts, and the prevention 
of ventilator-induced lung injury (VILI) by a better 
distribution of tidal volume (4).
Moreover, lung recruitment may explain the reduction 
in pulmonary vascular resistance and right heart dimensions 
observed in PP (5).
However, despite this strong physiological rationale, 
early randomized clinical trials that tested the efficacy of 
PP left clinicians with consistent uncertainty on its real 
benefits on mortality rates. Advocated mechanisms for 
this low efficacy were lack of inclusion of the most severe 
forms of hypoxemia, the “low dose” of PP administered 
(less than 6 h/d), and the lack of use of protective 
mechanical ventilation (6). Despite these limitations, the 
survival rate increased among subjects with most severe 
ARDS treated in prone position (7).
An important breakout on PP can be identified in the 
PROSEVA trial, that showed a major decrease in mortality 
rate at 28 and 90 days in subjects treated with PP (The 
28-day mortality was 16.0% in the prone group and 32.8% 
in the supine group; 90-day mortality was 23.6% in the 
prone group versus 41.0% in the supine group) (8). This 
was a multi-center randomized controlled trial on early 
application of prolonged prone position (16 h/d) in subjects 
with severe ARDS. One of the main features of this trial was 
the attempt to sharply define ARDS severity and ventilation 
parameters cutoffs (PaO2/FIO2 <150, PEEP >5 cmH2O, 
FIO2 0.6, with an average VT of 6.1 mL/kg of predicted 
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body weight).
In this perspective, the correct choice of patients and 
early initiation of prone therapy appear to be key factors 
for the success of this strategy. Although Munshi et al. (9) 
clearly stated that PP is likely to reduce mortality among 
patients with severe ARDS if applied for at least 12 hours 
daily, it was still unclear how this findings modified the 
actual clinical practice in the ICU settings. The LUNG 
SAFE study shows that the rate of its application is 
extremely low (16.3%) (2).
Doubts had arisen that this low rate could be explained 
on the base that clinicians still perceived the evidence level 
as weak. Other explanations could be that the process of 
moving a patient to a prone position is often considered 
as labor-intensive and, if not correctly performed, it can 
increase the risk of accidental removal of the endotracheal 
tube, drains, or catheters, as well as the development of 
pressure sores.
Under these circumstances, a study specifically designed 
to enlighten the present situation on prevalence of PP use 
and the perception of its effectiveness as well as the possible 
reasons for not using it, is by all means required and 
welcome.
Recently, Guérin and coworkers reported results of the 
APRONET study (10). This is a prospective international 
prevalence study, performed on a single day four times 
in April, July and October 2016 and January 2017. Over 
this period, 6,723 patients in 141 ICUs from 20 countries 
(77% European) were screened. Eventually, 735 patients 
with ARDS were monitored for use of PP, gas exchange, 
ventilator settings and plateau pressure. Complications 
and reasons for not using PP were also recorded. The 
main finding was that 32.9% of patients with severe ARDS 
received PP, showing low complication rates and significant 
improvements in terms of oxygenation and driving pressure. 
The APRONET trial is therefore the first work that 
focuses on the prevalence of the use of PP in a substantial 
number of ICU centers and countries and that filed a list of 
the reasons not to use it.
Can we say that the picture substantially changed 
since the LUNGSAFE trial? According to the Authors, 
the scenario has significantly progressed in the last two 
years. The study found that PP was used in 32.9% of 
severe ARDS patients with a low rate of complications and 
significant results in terms of oxygenation increase and 
driving pressure decrease. It is interesting to point out that 
counting the patients who met the Proseva criteria the rate 
of pronating rises to 40.2%. However, if we consider the 
overall population of the study (735 patients that fulfilled 
the ARDS criteria vs. 2,377 in the LUNGSAFE study), the 
rate of PP goes down to 13.7% (101 patients).
Can we consider this a reliable picture of the present 
use of PP in the daily practice? The study design may arise 
some reasonable doubts. 
First, the prevalence data collection was based on four 
days distributed in different seasons of the year between 
April 2016 and January 2017. This could be a point of 
strength for the study when looking at the prevalence of 
ARDS cases on a seasonal base but on the other hand, 
each center had the freedom to choose to participate how 
many times as it could, and to join one or more of the 
predetermined days and it is therefore reasonable to think 
(and Authors pointed it up) that the prescheduling of the 
deadlines could have boosted the use of PP in anticipation 
of the participation to the study. In fact, despite the 
expected seasonal trends in ARDS prevalence (lower in 
summer and higher in winter and spring) the prevalence of 
PP did not differ accordingly. 
Second,  another possible reason to suspect  an 
overestimation of PP is the choice and the number of 
the ICUs included in this work. In fact, the APRONET 
enrolled 141 ICUs from 20 countries (mostly European). 
Furthermore, most of the ICUs recruited were located in 
France, Spain and Italy which are the countries that have 
shown the higher interest in ARDS treatment and have 
published the larger studies on PP, so far.
Some concerns still arise when it comes to the choice of 
the patients to pronate and, even most important, the ones 
not to. Looking at the reasons for not pronating, stands 
out the clinician misunderstandings about the severity of 
hypoxemia (accounting for 64.3% of all cases). One of the 
most challenging issues of PP treatment for ARDS patients 
has always been the definition of the specific thresholds of 
PaO2/FiO2 that might benefit the most from this strategy. 
The Proseva trial represents a cornerstone on this issue 
and the APRONET study seems to confirm the point. As 
previously pointed out, the 40% of patients meeting the 
Proseva criteria in this study had been pronated, reflecting 
the impact of this trial on the clinicians perception. This 
same impact may as well be reflected by the overall length 
of the PP treatment, that is now assessed on 18 (from 16 to 
23) hours for the first session, showing a larger consensus 
on the evidence that duration of positioning consistently 
affects the efficacy of PP. But more interestingly, how can 
we explain the choice not to pronate the 60% of patients 
meeting the Proseva criteria of severe ARDS, and, even 
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more significant, how can we explain the choice to pronate 
a number of patients with mild or moderate ARDS?
One possible answer is that a substantial number of 
patients that showed a PaO2/FiO2 ratio <150 were not 
considered hypoxemic enough to undergo PP. Still, this 
doesn’t match with the 15 patients pronated with a P/F 
ratio between 295 and 171.
According to this scenario, we have to assume that 
there is still a deep confusion and a lack of homogeneity 
when it comes to recognition of the severity of ARDS and 
progression of treatments. 
Consolidated evidence shows that the greatest benefit 
from each therapeutic strategy can be achieved only if 
applied to a specific level of ARDS progression (11). 
Given that Lung Protective Ventilation should be the 
base-line of ARDS treatment from the start, patients with 
a P/F ratio between 200 and 150 should progressively be 
treated with higher levels of PEEP and neuromuscular 
blockage. Subsequently, PP represents the third line of 
treatment after which (in presence of a P/F ratio declining 
to <100) rescue treatments should be considered (12).
The second most important reason not to pronate (that 
could partially help to explain the 49 severe ARDS patients 
that were not pronated), is the hemodynamic instability. 
This element concurs at the idea that ARDS treatment 
strategies have not been fully understood and embraced 
by ICUs physicians, given that pronating have shown to 
improve hemodynamic rather than worsen it.
Lastly, looking at the possible reasons not to pronate 
a patient, stands out the undefined voice (others) that 
accounts for the 6% of the cases (44 patients). It is rational 
to think that this percentage could be referred to all the 
logistic and practical reasons that have always played an 
important role in the low application of PP, so far.
The rates of possible complications have been pointed 
out, in the past studies, as one of the criticisms in PP 
practice. The chance of endotracheal tube, drains or 
catheters removal, and the higher incidence of pressure 
sores may have accounted for a certain part of not 
considering PP as a feasible strategy. The Apronet study 
deviates from this tendency. Complications were reported 
in 12 of 101 pronated patients. Also in this case, these data 
can be interpreted as either due to (I) improvement of ICUs 
standards of practice thanks to a more frequent use of PP; 
(II) selection of ICUs that have always been more open to 
the PP practice and therefore have developed the skills to 
perform it in the most efficient and safe way.
With all these limitations, the APRONET study 
confirms the efficacy of PP. A significant improvement in 
oxygenation at the first session of PP was observed, with 
a reduction of driving pressure (with no variations on Vt). 
This could represent an interesting finding since driving 
pressure has been pointed as a strong predictor of mortality 
in ARDS patients. With all the limitations of the case, 
the APRONET study gives a first sight on the perception 
among clinicians of the use of PP.
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